We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

57 hedge funds and large institutions have $51.4M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

172% more call options, than puts

Call options by funds: $508K | Put options by funds: $187K

2% more funds holding

Funds holding: 56 → 57 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

13% less capital invested

Capital invested by funds: $59.3M → $51.4M (-$7.88M)

Holders
57
Holders Change
+1
Holders Change %
+1.79%
% of All Funds
0.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
17
Reduced
17
Closed
14
Calls
$508K
Puts
$187K
Net Calls
+$321K
Net Calls Change
+$177K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6.9M
2
GC
Greenlight Capital
New York
+$3.87M
3
SCM
Sio Capital Management
New York
+$2.62M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.87M
5
GCP
GSA Capital Partners
United Kingdom
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$4.65M
2
State Street
State Street
Massachusetts
-$1.29M
3
GCM
Glenview Capital Management
New York
-$739K
4
Northern Trust
Northern Trust
Illinois
-$703K
5
N
Nuveen
North Carolina
-$694K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$13.1M +$3.87M +35,000 +35%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.22M +$1.87M +16,950 +35%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$5.99M +$6.9M +62,500 New
SCM
4
Sio Capital Management
New York
$4.16M +$2.62M +23,750 +121%
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$3.04M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$2.04M +$1.26M +11,449 +117%
GCP
7
GSA Capital Partners
United Kingdom
$1.66M +$1.57M +14,250 +466%
JAMONY
8
Jacob Asset Management of New York
California
$1.66M +$608K +5,500 +47%
PCM
9
Prelude Capital Management
New York
$1.49M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.12M -$451K -4,083 -26%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$978K +$717K +6,490 +174%
Two Sigma Investments
12
Two Sigma Investments
New York
$886K +$512K +4,631 +100%
Millennium Management
13
Millennium Management
New York
$834K +$706K +6,388 +276%
FWM
14
Frontier Wealth Management
Missouri
$695K – – –
Marshall Wace
15
Marshall Wace
United Kingdom
$653K +$753K +6,821 New
Morgan Stanley
16
Morgan Stanley
New York
$574K +$527K +4,772 +394%
Goldman Sachs
17
Goldman Sachs
New York
$525K +$30K +272 +5%
Deutsche Bank
18
Deutsche Bank
Germany
$479K +$488K +4,415 +755%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$418K -$197K -1,784 -29%
BlackRock
20
BlackRock
New York
$416K -$4.65M -42,122 -91%
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$412K +$413K +3,736 +665%
GPCM
22
Granite Point Capital Management
Massachusetts
$389K +$448K +4,060 New
E
23
Ergoteles
New York
$367K +$423K +3,833 New
First Trust Advisors
24
First Trust Advisors
Illinois
$350K +$107K +972 +36%
TEE
25
Tibra Equities Europe
United Kingdom
$318K +$367K +3,320 New
1
2 3

NBSE Hedge Fund Activity: Q2 2021 in Review

57 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2021, worth a combined $51.4M — down 13% from $59.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new NBSE positions and 14 closed out — a net gain of 1 holder — while 17 added to existing stakes and 17 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.9M. The largest seller was BlackRock, cutting an estimated $4.65M.

  • 57 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2021, up from 56 in Q1 2021.
  • Funds reported $51.4M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2021, down 13% quarter-over-quarter.
  • 15 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of +1 holder.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2021 was Point72 Asset Management, an estimated $6.9M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $4.65M sold.

Based on aggregated 13F filings for Q2 2021.